Division of Infectious Diseases, Department of Internal Medicine I, German Center for Infection Research, University of Tübingen, Tübingen, Germany.
Division of Infectious Diseases, Department of Diagnostic and Public Health, G.B. Rossi University Hospital, University of Verona, Verona, Italy.
Gastroenterology. 2018 Nov;155(5):1372-1382.e17. doi: 10.1053/j.gastro.2018.07.007. Epub 2018 Jul 7.
BACKGROUND & AIMS: In 2017, the World Health Organization (WHO) designated clarithromycin-resistant Helicobacter pylori a high priority for antibiotic research and development. However, there are no clear data on the global distribution of resistance or its clinical effects. We performed a systematic review and meta-analysis to assess the distribution of H pylori resistance to commonly used antibiotics and to measure the association between antibiotic resistance and treatment failure.
We searched publication databases for studies that assessed rates of H pylori resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, or tetracycline. Pooled estimates of primary and secondary resistance and 95% confidence intervals (CIs) were grouped by WHO region. The association between antibiotic resistance and treatment failure was measured by extracting data on treatment efficacy in patients with resistant and susceptible isolates and pooling odds ratios with 95% CIs.
We identified 178 studies, comprising 66,142 isolates from 65 countries. Primary and secondary resistance rates to clarithromycin, metronidazole, and levofloxacin were ≥15% in all WHO regions, except primary clarithromycin resistance in the Americas (10%; 95% CI, 4%-16%) and South-East Asia region (10%; 95% CI, 5%-16%) and primary levofloxacin resistance in the European region (11%; 95% CI, 9%-13%). There was considerable heterogeneity (I > 75%) among all analyses-this might have resulted from the grouping of resistance rates by country. Increasing antibiotic resistance was observed in most WHO regions. Resistance to clarithromycin was significantly associated with failure of clarithromycin-containing regimens (odds ratio, 6.97; 95% CI, 5.23-9.28; P < .001).
Resistance of H pylori to antibiotics has reached alarming levels worldwide, which has a great effect on efficacy of treatment. Local surveillance networks are required to select appropriate eradication regimens for each region.
2017 年,世界卫生组织(WHO)将克拉霉素耐药幽门螺杆菌列为抗生素研发的高度优先事项。然而,目前尚无关于全球耐药分布及其临床影响的明确数据。我们进行了系统评价和荟萃分析,以评估常用抗生素治疗幽门螺杆菌的耐药分布,并测量抗生素耐药性与治疗失败之间的关联。
我们检索了评估克拉霉素、甲硝唑、左氧氟沙星、阿莫西林或四环素耐药率的研究出版物数据库。根据世界卫生组织区域,对原发性和继发性耐药的汇总估计值及其 95%置信区间(CI)进行分组。通过提取耐药和敏感分离株患者治疗效果的数据,测量抗生素耐药性与治疗失败之间的相关性,并汇总优势比及其 95%CI。
我们确定了 178 项研究,共涉及来自 65 个国家的 66142 个分离株。除美洲(10%;95%CI,4%-16%)和东南亚(10%;95%CI,5%-16%)地区原发性克拉霉素耐药率以及欧洲地区原发性左氧氟沙星耐药率(11%;95%CI,9%-13%)外,所有世界卫生组织区域的克拉霉素、甲硝唑和左氧氟沙星的原发性和继发性耐药率均≥15%。所有分析中都存在很大的异质性(I > 75%)-这可能是由于按国家分组的耐药率所致。在大多数世界卫生组织区域中,抗生素耐药性呈上升趋势。克拉霉素耐药与克拉霉素含治疗方案失败显著相关(比值比,6.97;95%CI,5.23-9.28;P <.001)。
幽门螺杆菌对抗生素的耐药性已在全球范围内达到令人担忧的水平,这对治疗效果有很大影响。需要建立当地的监测网络,为每个地区选择合适的根除方案。